PT010 is a fixed triple-combination product consisting of a long-acting muscarinic antagonist (LAMA [glycopyrrolate]), a long-acting beta 2 agonist (LABA [formoterol]), and an inhaled corticosteroid (ICS [budesonide]). PT010 is in Phase III development for the treatment of moderate to very severe COPD, and in Phase II development for the treatment of moderate to severe persistent asthma.
LIST OF FIGURES
13 Figure 1: PT010 for COPD – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of PT010 for COPD
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of PT010 for COPD
17 Figure 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: PT010 drug profile
7 Table 2: PT010 Phase III data in COPD
9 Table 3: PT010 Phase III trials in COPD
18 Table 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.